Combination therapy of two Vertex Pharmaceuticals drugs hit a big mark in the treatment of cystic fibrosis. Adam Feuerstein, senior columnist at TheStreet, breaks down the study results of the TRAFFIC and TRANSPORT phase III studies, which when pooled together, resulted in a 3.3% improvement in cystic fibrosis patients' lung function on an absolute basis. Feuerstein reveals whether the results are clinically meaningful and how significant they're likely to be regarded by industry watchers. With the stock soaring pre-market on the news, Feuerstein also explains what the results should mean to shares of Vertex going forward.

If you liked this article you might like

Vertex Pharmaceuticals Could Be Headed Higher Once Again

Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers

10 High-Yielding Stocks to Own Ahead of a Surprising Late Summer Market Swoon

Vertex Pharmaceuticals: Looking East, West and to the Quants

Vertex Pharmaceuticals: Looking East, West and to the Quants